288 related articles for article (PubMed ID: 26640980)
1. Persistence, adherence, and all-cause healthcare costs in atazanavir- and darunavir-treated patients with human immunodeficiency virus in a real-world setting.
Farr AM; Johnston SS; Ritchings C; Brouillette M; Rosenblatt L
J Med Econ; 2016; 19(4):386-96. PubMed ID: 26640980
[TBL] [Abstract][Full Text] [Related]
2. No difference in persistence to treatment with atazanavir or darunavir in HIV patients in a real-world setting.
Farr AM; Johnston SS; Ritchings C; Brouillette M; Rosenblatt L
J Int AIDS Soc; 2014; 17(4 Suppl 3):19538. PubMed ID: 25394047
[TBL] [Abstract][Full Text] [Related]
3. Short-term cost analysis of raltegravir versus atazanavir + ritonavir or darunavir + ritonavir for treatment-naive adults with HIV-1 infection in the United States.
Brogan AJ; Davis AE; Goodwin B
PLoS One; 2018; 13(8):e0203293. PubMed ID: 30161205
[TBL] [Abstract][Full Text] [Related]
4. Effects of once-daily darunavir/ritonavir versus atazanavir/ritonavir on insulin sensitivity in HIV-infected persons over 48 weeks: results of an exploratory substudy of METABOLIK, a phase 4, randomized trial.
Overton ET; Tebas P; Coate B; Ryan R; Perniciaro A; Dayaram YK; De La Rosa G; Baugh BP
HIV Clin Trials; 2016 Mar; 17(2):72-7. PubMed ID: 26917112
[TBL] [Abstract][Full Text] [Related]
5. Simplification to dual-therapy containing lamivudine and darunavir/ritonavir or atazanavir/ritonavir in HIV-infected patients on virologically suppressive antiretroviral therapy.
Calza L; Cafaggi M; Colangeli V; Borderi M; Barchi E; Lanzafame M; Nicole' S; Degli Antoni AM; Bon I; Re MC; Viale P
Infect Dis (Lond); 2018 May; 50(5):352-360. PubMed ID: 29210336
[TBL] [Abstract][Full Text] [Related]
6. Improvement in lipids after switch to boosted atazanavir or darunavir in children/adolescents with perinatally acquired HIV on older protease inhibitors: results from the Pediatric HIV/AIDS Cohort Study.
Jao J; Yu W; Patel K; Miller TL; Karalius B; Geffner ME; DiMeglio LA; Mirza A; Chen JS; Silio M; McFarland EJ; Van Dyke RB; Jacobson D;
HIV Med; 2018 Mar; 19(3):175-183. PubMed ID: 29159965
[TBL] [Abstract][Full Text] [Related]
7. Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir.
Brown TT; Moser C; Currier JS; Ribaudo HJ; Rothenberg J; Kelesidis T; Yang O; Dubé MP; Murphy RL; Stein JH; McComsey GA
J Infect Dis; 2015 Oct; 212(8):1241-9. PubMed ID: 25948863
[TBL] [Abstract][Full Text] [Related]
8. Economic and health-related quality-of-life (HRQoL) comparison of lopinavir/ritonavir (LPV/r) and atazanavir plus ritonavir (ATV+RTV) based regimens for antiretroviral therapy (ART)-naïve and -experienced United Kingdom patients in 2011.
Simpson KN; Baran RW; Collomb D; Beck EJ; Van de Steen O; Dietz B
J Med Econ; 2012; 15(4):796-806. PubMed ID: 22563716
[TBL] [Abstract][Full Text] [Related]
9. Ritonavir-boosted darunavir is rarely associated with nephrolithiasis compared with ritonavir-boosted atazanavir in HIV-infected patients.
Nishijima T; Hamada Y; Watanabe K; Komatsu H; Kinai E; Tsukada K; Teruya K; Gatanaga H; Kikuchi Y; Oka S
PLoS One; 2013; 8(10):e77268. PubMed ID: 24130871
[TBL] [Abstract][Full Text] [Related]
10. Comparative incidence and health care costs of medically attended adverse effects among U.S. Medicaid HIV patients on atazanavir- or darunavir-based antiretroviral therapy.
Johnston SS; Juday T; Esker S; Espindle D; Chu BC; Hebden T; Uy J
Value Health; 2013; 16(2):418-25. PubMed ID: 23538194
[TBL] [Abstract][Full Text] [Related]
11. Comparison of atazanavir/ritonavir and darunavir/ritonavir based antiretroviral therapy for antiretroviral naïve patients.
Antoniou T; Szadkowski L; Walmsley S; Cooper C; Burchell AN; Bayoumi AM; Montaner JS; Loutfy M; Klein MB; Machouf N; Tsoukas C; Wong A; Hogg RS; Raboud J;
BMC Infect Dis; 2017 Apr; 17(1):266. PubMed ID: 28399819
[TBL] [Abstract][Full Text] [Related]
12. Healthcare costs associated with antiretroviral adherence among medicaid patients.
Pruitt Z; Robst J; Langland-Orban B; Brooks RG
Appl Health Econ Health Policy; 2015 Feb; 13(1):69-80. PubMed ID: 25403718
[TBL] [Abstract][Full Text] [Related]
13. Effects of atazanavir, darunavir, and raltegravir on fat and muscle among persons living with HIV.
Adrian S; Miao H; Feng H; Scherzinger A; Nardini G; Beghetto B; Roncaglia E; Ligabue G; Milic J; Guaraldi G; Lake JE; Erlandson KM
HIV Res Clin Pract; 2020 Aug; 21(4):91-98. PubMed ID: 32878571
[TBL] [Abstract][Full Text] [Related]
14. Real-World Health Plan Data Analysis: Key Trends in Medication Adherence and Overall Costs in Patients with HIV.
Kangethe A; Polson M; Lord TC; Evangelatos T; Oglesby A
J Manag Care Spec Pharm; 2019 Jan; 25(1):88-93. PubMed ID: 30589631
[TBL] [Abstract][Full Text] [Related]
15. Inflammatory effects of atazanavir/ritonavir versus darunavir/ritonavir in treatment naïve, HIV-1-infected patients.
Dentone C; Di Biagio A; Cozzi Lepri A; Fenoglio D; Filaci G; Lichtner M; Carrara S; Giacometti A; Sighinolfi L; Marchetti G; Antinori A; D'arminio Monforte A;
HIV Clin Trials; 2018 Aug; 19(4):158-162. PubMed ID: 30422095
[TBL] [Abstract][Full Text] [Related]
16. Long-Term Efficacy, Tolerability, and Renal Safety of Atazanavir/Ritonavir-based Antiretroviral Therapy in a Cohort of Treatment-Naïve Patients with HIV-1 Infection: the REMAIN Study.
Teófilo E; Rocha-Pereira N; Kuhlmann B; Antela A; Knechten H; Santos J; Jiménez-Expósito MJ;
HIV Clin Trials; 2016 Feb; 17(1):17-28. PubMed ID: 26899539
[TBL] [Abstract][Full Text] [Related]
17. Risk of cardiovascular events among patients with HIV treated with atazanavir-containing regimens: a retrospective cohort study.
Rosenblatt L; Farr AM; Nkhoma ET; Nelson JK; Ritchings C; Johnston SS
BMC Infect Dis; 2016 Sep; 16():492. PubMed ID: 27643691
[TBL] [Abstract][Full Text] [Related]
18. Durability and tolerability of first-line regimens including two nucleoside reverse transcriptase inhibitors and raltegravir or ritonavir boosted-atazanavir or -darunavir: data from the ICONA Cohort.
d'Arminio Monforte A; Lorenzini P; Cozzi-Lepri A; Mussini C; Castagna A; Baldelli F; Puoti M; Vichi F; Maddaloni A; Lo Caputo S; Gianotti N; Antinori A;
HIV Clin Trials; 2018 Apr; 19(2):52-60. PubMed ID: 29493419
[TBL] [Abstract][Full Text] [Related]
19. Safety of darunavir and atazanavir in HIV-infected children in Europe and Thailand.
European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) Study Group in EuroCoord
Antivir Ther; 2016; 21(4):353-8. PubMed ID: 26561496
[TBL] [Abstract][Full Text] [Related]
20. Is the Risk of Myocardial Infarction in People With Human Immunodeficiency Virus (HIV) Associated With Atazanavir or Darunavir? A Nested Case-Control Study Within the French Hospital Database on HIV.
Costagliola D; Potard V; Lang S; de Castro N; Cotte L; Duval X; Duvivier C; Grabar S; Mary-Krause M; Partisani M; Ronot-Bregigeon S; Simon A; Tattevin P; Weiss L; Zucman D; Katlama C; Raffi F; Boccara F
J Infect Dis; 2020 Feb; 221(4):516-522. PubMed ID: 31828320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
